3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
68
Carcinoma, Non-Small-Cell Lung
64
Multiple Myeloma
52
Prostatic Neoplasms
47
Colorectal Neoplasms
40
Leukemia, Myeloid, Acute
39
Neoplasms
35
Melanoma
31
Lymphoma
31
Ovarian Neoplasms
29
Lymphoma, Non-Hodgkin
28
Sarcoma
27
Lung Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
24
Neoplasm Metastasis
24
Carcinoma, Hepatocellular
24
Pancreatic Neoplasms
22
Endometrial Neoplasms
22
Hodgkin Disease
21
Glioma
21
Recurrence
20
Leukemia, Lymphocytic, Chronic, B-Cell
20
Carcinoma, Renal Cell
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Urinary Bladder Neoplasms
18
Myelodysplastic Syndromes
18
Lymphoma, Large B-Cell, Diffuse
18
Head and Neck Neoplasms
18
Rectal Neoplasms
15
Hematologic Neoplasms
15
Interventions
durvalumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Docetaxel
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Vaccinia
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled